Therapy of androgenetic sympatomatology with cyproterone acetate and ethinyl estradiol.
The effectiveness of therapy with cyproterone acetate and ethinyl estradiol was studied in 103 women. Acne and seborrhea responded best with 91.7 and 93.3% respectively, including complete and partial therapeutic success. For hirsutism complete remission and partial improvement were found in 75.3% of the treated women. Under therapy, body weight did not change in 51.9%, while 24.7% of the patients gained weight and 23.4% lost weight. The cycle length remained normal after therapy in 35.8%. Normalization or improvement was found in 54.7%. In 6.3% no improvement was noted after therapy and in 3.2% cycle irregularity developed in women with previous undisturbed pattern. According to BBT, improvement of the functional capacity of the reproductive system was found in 32.9% of the patients. Only 3% of the women studied demonstrated a deterioration. The 17-ketosteroid excretion was diminished in 35.3% after therapy and remained unchanged in 64.7%. The therapeutic regimen used for the study was well tolerated and good cycle control was obtained.
D015068:17-Ketosteroids / Q000652:urine; D000152:Acne Vulgaris / Q000188:drug therapy*; D000293:Adolescent; D000328:Adult; D001831:Body Temperature; D001835:Body Weight; D003534:Cyproterone / Q000627:therapeutic use*; D012628:Dermatitis, Seborrheic / Q000188:drug therapy*; D004997:Ethinyl Estradiol / Q000627:therapeutic use*; D005260:Female; D006628:Hirsutism / Q000188:drug therapy*; D006801:Humans; D008598:Menstruation; D008599:Menstruation Disturbances / Q000150:complications; D012075:Remission, Spontaneous
D015068:17-Ketosteroids; D004997:Ethinyl Estradiol; D003534:Cyproterone